Innate Pharma SA (IPHA) Company Sales

The sales history of Innate Pharma S.A. (IPHA) demonstrates the impact of unique platforms designed to train NK cells to destroy tumors. Growth is driven by the expansion of monoclonal antibodies through global alliances, although cash flow volatility is caused by a dependence on partner payments and the risk of early-stage program closures. The sales dynamics on this chart highlight these factors, and the 0.00 metric confirms the current level of operating revenue.

innate-pharma.com (IPHA): Company Revenue from 07/04/2022 to 11/13/2026

Analytical breakdowns for Innate Pharma (IPHA)

- stock value and consensus price forecast:

Stock Quotes Innate Pharma S.A|IPHA - Price Target Chart

- market capitalization details:

Market Valuation Innate Pharma S.A.|IPHA - Real Price to Acquire Entire Company

- balance sheet equity data:

Book Value per Share Innate Pharma|IPHA - Company Book Value|Capitalization to Book Value Ratio innate-pharma.com|IPHA - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

IPHA - Company Net Income|Expected Net Income Innate Pharma S.A.|IPHA - P/E Multiple|Forward P/E Multiple innate-pharma.com|IPHA - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Innate Pharma S.A.|IPHA - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Innate Pharma|IPHA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months innate-pharma.com|IPHA - Earnings per share growth in current year|Projected earnings per share growth rate for next year Innate Pharma S.A.

- sales volume and revenue indicators:

IPHA - Company Revenue|Company Revenue Forecast Innate Pharma S.A|IPHA - P/S Multiple|Forward P/S Multiple Innate Pharma S.A.

General company analysis:Innate Pharma S.A, IPHA

For Innate Pharma S.A., an oncology expert, the company's sales chronology reflects the commercialization efficiency of its NK-cell antibody platform. The indicator tracks aggregate daily revenue, serving as an objective measure of market demand for innovation. The current value of 0.00 demonstrates the scale of operational inflows from partnerships with pharma behemoths. The metric's dynamics are sensitive to clinical trial stages and royalty payments. Steady growth confirms the fundamental resilience of the business.

Key competitors